Valuation: Resverlogix Corp.

Market Cap 25.64M 18.2M 15.99M 14.87M 13.64M 1.75B 26.03M 177M 68.98M 862M 68.34M 66.86M 2.98B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 111M 79.12M 69.49M 64.63M 59.3M 7.62B 113M 767M 300M 3.75B 297M 291M 12.95B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 day+5.00%
1 week+5.00%
Current month+16.67%
1 month+10.53%
3 months+5.00%
6 months+5.00%
Current year+5.00%
1 week 0.1
Extreme 0.095
0.1
1 month 0.09
Extreme 0.09
0.11
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 24/04/2003
Director of Finance/CFO 78 28/10/2009
Chief Tech/Sci/R&D Officer - 14/08/2022
Director TitleAgeSince
Chairman - 03/04/2016
Director/Board Member 56 14/10/2009
Director/Board Member 66 28/09/2010
Date Insider Type Main position Quantity % Market Cap.
04/05/26 Option

Chief Financial Officer

300,000 0.0949%
04/05/26 Option

Chief Financial Officer

300,000 0.0949%
06/03/26 Option

Chief Financial Officer

62,500 0.0217%
Change 5-day change 1-year change 3-year change Capi.($)
+5.00%+5.00%-22.22%+5.00% 25.64M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -0.44%+1.15%+33.95%+150.97% 24.01B
Weighted average by Cap. -0.87%+2.10%+39.69%+133.48%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.42M -4.76M -4.43M -4.06M -522M -7.75M -52.58M -20.54M -257M -20.35M -19.91M -887M -7.77M -5.52M -4.84M -4.5M -4.13M -531M -7.89M -53.49M -20.9M -261M -20.7M -20.26M -903M
Net Debt 81.87M 58.14M 51.06M 47.48M 43.57M 5.6B 83.13M 564M 220M 2.75B 218M 214M 9.52B 85.79M 60.92M 53.5M 49.76M 45.66M 5.87B 87.11M 591M 231M 2.88B 229M 224M 9.97B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
24/07/26 CA$0.1050 +5.00% 37,116
23/07/26 CA$0.1000 -4.76% 43,914
22/07/26 CA$0.1050 +5.00% 56,400
21/07/26 CA$0.1000 0.00% 500
20/07/26 CA$0.1000 0.00% 2,000